melanoma

News

Opdivo set to take on Keytruda in adjuvant melanoma

Bristol-Myers Squibb's Opdivo has shown efficacy when used as a post-surgery (adjuvant) treatment for patients with melanoma, extending the time before the disease recurrence or patient dea

Oncology

A history of blood cancer treatment

Despite being one of the most common forms of cancer, awareness of blood cancer pales in comparison to other types of the disease.

News

ESMO: TIL therapy improves on Yervoy in melanoma trial

A personalised cell therapy based on tumour-infiltrating lymphocyte (TIL) cells has been shown to be more effective at improving progression-free survival than Bristol-Myers Squibb's immuno

News

Opdualag off to a flying start, says BMS CEO

Bristol-Myers Squibb's new immune checkpoint inhibitor combination Opdualag has only been on the US market for a few weeks but is already off to a "great start", according to chief executiv

News

Regeneron seeks CheckMate in immuno-oncology play

Regeneron has agreed an all-cash deal to acquire CheckMate Pharmaceuticals, adding immune activator vidutolimod to its cancer immunotherapy pipeline and ending a barren spell for M&A in

News